US Stem Cell Inc (USRM)

[Successful]

NEW YORK, NY / ACCESSWIRE / March 6, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and micro-cap public companies is issuing a comprehensive report with no obligation on U.S. Stem Cell, Inc. (USRM). Regenerative medicine is an emerging field for regeneration, repair & replacement of damaged human tissue and organs. The global regenerative medicine market is likely to reach a cumulative valuation of US $7 billion by 2019. USRM's focus is on moving up the value & marketing chain through signing new licensing agreements & entering into partnerships is likely to enrich its business strengths.

Key differentiating factors and recent developments are discussed here READ MORE

Copy and paste to your browser may be required to view the report- http://tradersnewssource.com/usrm-review/

USRM is in the process of launching new clinics and programs in the Middle East and China that will feature its technologies, therapies, and products. Also, it signed new licensing agreement with High Rising Group to open clinics throughout the Middle East, with locations in Dubai, Kuwait, and Qatar. Additionally, it entered into a partnership with Hong Kong Yihe Regeneration Medical Technology, to provide Chinese patients direct access to USRM's treatments and regenerative therapies at its Sunrise, Florida clinic.

An outlook over the near to medium term for USRM is available here READ MORE

Copy and paste to your browser may be required to view the report- http://tradersnewssource.com/usrm-review/

DISCLOSURE:

Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE, NASDAQ and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

TNS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a chartered financial analyst, for further information on analyst credentials, please email [e-mail]. Vikas Agrawal, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.